College of Medicine and Medical Sciences, Arabian Gulf University, Manama 329, Kingdom of Bahrain.
Acta Biochim Pol. 2023 Nov 22;70(4):729-733. doi: 10.18388/abp.2020_6426.
Imiquimod-induced psoriasis is widely-employed to study disease pathogenesis and to screen drugs. While the original protocol was published more than a decade ago and has been rigorously used in research since then, a modified protocol was described recently with several advantages including milder systemic manifestations although the disease morphology is highly conserved. Being a toll-like receptor 7 and 8 agonist, IL-23/IL-17 axis predominates in imiquimod-induced psoriasis. In addition, different immunocytes were described to aggravate or supress the disease. This article aims to review the currently available protocols of imiquimod-induced psoriasis in vivo, to characterize the model as described in literature and to define the five important independent factors adversely influencing the model which researchers should pay attention to.
咪喹莫特诱导的银屑病被广泛用于研究疾病发病机制和筛选药物。虽然最初的方案是十多年前发表的，并且从那时起就在研究中得到了严格的应用，但最近描述了一种改良的方案，具有包括更轻微的全身表现在内的几个优点，尽管疾病形态高度保守。作为 Toll 样受体 7 和 8 的激动剂，IL-23/IL-17 轴在咪喹莫特诱导的银屑病中占主导地位。此外，不同的免疫细胞被描述为加重或抑制疾病。本文旨在综述咪喹莫特诱导的银屑病的体内现有方案，描述文献中描述的模型，并确定五个重要的独立因素，这些因素对模型有不利影响，研究人员应予以关注。
